Monthly Archives: February 2017

Missing teen with diabetes believed to be headed to Georgia – 11alive.com

Posted: February 21, 2017 at 11:40 pm

Makayla Mattei, 15, went missing from her Virginia home on Friday morning. Her mom is worried that a stranger online lured her daughter to Georgia. Makayla is diabetic.

Ellison Barber and 11Alive , WUSA 12:54 PM. EST February 21, 2017

DUMFRIES, VA (WUSA9) - The family of a missing 15-year-old is afraid their daughter is with a stranger she met on the internet.They are originally from Atlanta and the mom said it is possible the teen may try to make her way toward Georgia.

"We haven't seen her. We haven't heard from her," said Chermene Shaw. "It feels like someone just ripped my heart out of my chest and there's a hole."

Shaws daughter, Makayla "Kayla" Phyllis Mattei, was last seen on Friday morning when she left to attend school at Forest Park High School in Dumfires, Virginia. Shaw says Makayla did not show up for school and hasn't been seen or heard from since.

This is the first time Makayla has ever left home, Shaw told WUSA9, and she's afraid the teen did it because of someone she met on the internet.

A few months ago, Shaw said she noticed her daughter talking to someone through social media.

"We believe she was talking to someone that she believed to be her age We think that this may be an adult, Shaw explained. "They don't live around here. They don't go to school anywhere."

Makayla has diabetes and needs insulin injections. Shaw said when her daughter left home she had medication with her, but she might not use it properly and she does not have a phone.

The mom took her phone away when she noticed her daughter talking to the stranger, and she had started to look through it.

"I had already taken it from her to look into. Even to hand off to the police initially, because my concern already was that there was possibly an adult trying to maybe even lure my child. It seemed so farfetched at the time, she said.

"You know your great fear, you think is to not have your child near to you but to not have them near to you and have them near to someone that possibly means them harm - I feel paralyzed."

Shaw says she and her family have spent days handing out missing flyers to as many people as they can.

"I want Makayla to know that we love her. Everyone is looking for her. Your family. We miss you, Shaw said. "We just want you to come home. If anyone has my daughter - we will find you. I will never stop looking until I get my baby back."

Makaylawas last seen wearing jeans, a pink hoodie, and carrying a dark book bag with the words Georgia State University on the front pocket.

Shaw said the family moved to Dumfries about a year ago. They are originally from Atlanta and Shaw said it is possible Makayla may try to make her way toward Georgia.

If you have any information about Makayla's whereabouts, please contact the Dumfries Police Department at (703)-792-6500.

( 2017 WUSA)

Link:
Missing teen with diabetes believed to be headed to Georgia - 11alive.com

Posted in Diabetes | Comments Off on Missing teen with diabetes believed to be headed to Georgia – 11alive.com

Researchers implicate suspect in heart disease linked to diabetes – Medical Xpress

Posted: February 21, 2017 at 11:40 pm

February 21, 2017 by Mark Derewicz Top Row: Heart arteries in normal mice, diabetic mice, and normal mice with deleted IRS-1 gene. Bottom row: when artery is wounded, diabetic mice with less IRS-1 and normal mice with deleted IRS-1 gene show much greater blockage due to over-proliferation of smooth muscle cells. Credit: Clemmons Lab, UNC School of Medicine

People with diabetes are at high risk of developing heart disease. Despite knowing this, scientists have struggled to trace the specific biology behind that risk or find ways to intervene. Now, UNC School of Medicine researchers have hunted down a possible culprit - a protein called IRS-1, which is crucial for the smooth muscle cells that make up veins and arteries.

According to a study published in the Journal of Biological Chemistry, too little of IRS-1 causes cells to revert to a "dedifferentiated" or stem-cell like state, and this may contribute to the buildup of plaque in the heart's arteries, a condition known as atherosclerosis, which increases the risk of heart attack, stroke, and other forms of heart disease.

"When diabetes is poorly managed, your blood sugar goes up and the amount of this protein goes down, so the cells become subject to abnormal proliferation," said senior author David R. Clemmons, MD, Sarah Graham Kenan Professor of Medicine at the UNC School of Medicine. "We need to conduct more studies, but we think this cell pathway may have significant implications for how high blood glucose leads to atherosclerosis in humans."

The research could bring scientists one step closer to finding drugs to help stave off heart disease in people with diabetes, who are twice as likely to have heart disease or experience a stroke, as compared to people without diabetes. People with diabetes also tend to experience major cardiac events at a younger age.

The study focused on the cells that form the walls of veins and arteries, known as vascular smooth muscle cells. The main function of these cells is to contract whenever the heart beats, helping to push oxygen-rich blood to the body's tissues. When plaque builds up along the arterial walls, these cells gradually lose their ability to contract.

In their previous work, Clemmons and colleagues discovered that diabetes can trigger an abnormal cell signaling pathway that causes vascular smooth muscle cells to proliferate, which contributes to atherosclerosis. But their attempts to correct the abnormal signaling pathway didn't seem to completely solve the problem, leading them to suspect another factor.

In the new study, the team found that IRS-1 acts as an inhibitor of the abnormal signaling pathway thereby keeping the vascular smooth muscle cells differentiated, or specialized. In the absence of IRS-1, the cells revert to a stem-cell like state, which in turn activates the abnormal signaling pathway and promotes cell proliferation.

In people with diabetes, the presence of IRS-1 is strongly influenced by how well - or how poorly - blood sugar is kept in check. Previous studies have shown that patients who frequently or consistently have high blood sugar show dramatic reductions in IRS-1. The new study is the first to link this reduction with a predisposition for heart disease.

"The study suggests that you can't just inhibit the abnormal signaling, which we've already figured out how to do," Clemmons said. "Our work suggests you probably have to restore the normal signaling pathway, at least to some extent, in order to completely restore the cells to normal cell health, differentiation, and functioning."

As a next step, the Clemmons lab will look for things that might stimulate the synthesis of this protein even in the presence of high blood glucose.

To prove that IRS-1 acts as a brake on the abnormal signaling pathway that leads to cell proliferation, the team conducted experiments in three different types of mice: healthy mice, diabetic mice, and nondiabetic mice that were genetically engineered to produce no IRS-1. The scientists made a small incision in the blood vessels of the animals and then watched to see how the vascular smooth muscle cells reacted. In healthy mice, the incision stimulated wound healing but little cellular proliferation. In both the diabetic animals and the nondiabetic IRS-1 deficient animals, the researchers observed a marked increase in abnormal cellular proliferation.

The findings suggest that it may be possible to counteract the deleterious effects of high blood sugar on atherosclerosis by developing drugs that boost IRS-1.

Clemmons said the activities of IRS-1 might also play a role in other diabetes complications, such as eye and kidney disease. The researchers plan to study those potential links.

Explore further: Researchers use stem cells to regenerate the external layer of a human heart

A process using human stem cells can generate the cells that cover the external surface of a human heartepicardium cellsaccording to a multidisciplinary team of researchers.

After a heart attack, or myocardial infarction, a patient's long-term prognosis depends on the ability of the heart tissue to heal and remodel. Immune system activation and inflammatory responses that occur in the aftermath ...

According to the American Heart Association, approximately 2,200 Americans die each day from heart attacks, strokes and other cardiovascular diseases. The most common cause is blocked blood vessels that can no longer supply ...

People with any form of diabetes are at greater risk of developing cardiovascular conditions than people without the disease. Moreover, if they undergo an operation to open up a clogged artery by inserting a "stent" surgical ...

Patients with diabetes and metabolic syndrome are at increased risk of atherosclerosis and subsequent heart disease. It is not fully understood why atherosclerosis is increased with diabetes, but it has been proposed that ...

Scientists have implicated a type of stem cell in the calcification of blood vessels that is common in patients with chronic kidney disease. The research will guide future studies into ways to block minerals from building ...

People with diabetes are at high risk of developing heart disease. Despite knowing this, scientists have struggled to trace the specific biology behind that risk or find ways to intervene. Now, UNC School of Medicine researchers ...

A long-term study by Monash University researchers - the first of its kind - has found that gastric band surgery has significant benefits for moderately overweight people with type 2 diabetes. Previous studies have focused ...

Blood sugar triggers the secretion of insulin from cells in the pancreas, a process that is impaired in diabetes. A team of Yale researchers have identified a mechanism at the membranes of these pancreatic cells that controls ...

Alpha cells in the pancreas can be induced in living mice to quickly and efficiently become insulin-producing beta cells when the expression of just two genes is blocked, according to a study led by researchers at the Stanford ...

A new study by researchers at King's College London has found that patients with diabetes suffering from the early stages of kidney disease have a deficiency of the protective 'anti-ageing' hormone, Klotho.

Why do some people get Type 2 diabetes, while others who live the same lifestyle never do?

Adjust slider to filter visible comments by rank

Display comments: newest first

I was diagnosed with type 2 Diabetes and put on Metformin on June 26th, 2016. I started the ADA diet and followed it 100% for a few weeks and could not get my blood sugar to go below 140. Finally i began to panic and called my doctor, he told me to get used to it. He said I would be on metformin my whole life and eventually insulin. At that point i knew something wasn't right and began to do a lot of research. On August 13th I found Lisa's diabetes story (google " HOW EVER I FREED MYSELF FROM THE DIABETES " ) I read that article from end to end because everything the writer was saying made absolute sense. I started the diet that day and the next morning my blood sugar was down to 100 and now i have a fasting blood sugar between Mid 70's and the 80's. My doctor took me off the metformin after just three week of being on this lifestyle change. I have lost over 30 pounds and 6+ inches around my waist in a month

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more:
Researchers implicate suspect in heart disease linked to diabetes - Medical Xpress

Posted in Diabetes | Comments Off on Researchers implicate suspect in heart disease linked to diabetes – Medical Xpress

Son’s Diagnosis Fuels Multifaceted Approach to Treating Diabetes – Memphis Daily News

Posted: February 21, 2017 at 11:40 pm

VOL. 132 | NO. 38 | Wednesday, February 22, 2017

Dr. Kashif Latif dedicated his life to the research and treatment of diabetes after his son, who is now 20 years old, was diagnosed with juvenile diabetes when he was just 11 months old.

Dr. Kashif Latif has expanded treatment of diabetes beyond the walls of AM Diabetes and Endocrinology Center, establishing a 5K run for juvenile diabetes, providing education on a radio program and more.

(Daily News/Andrew J. Breig)

Now two decades later, Latif operates the AM Diabetes and Endocrinology Center in Bartlett, a comprehensive care facility for patients with diabetes and North Americas only specialized Insulin Pump Center.

Dealing with diabetes firsthand, I realized that there was a lot more to it than just the perception part, and I decided I wanted to make an impact for patients who are dealing with this disease day in and day out, Latif said. So I went back and trained, and then developed the center where we have a whole scope of services, with dieticians, diabetes educators and pathologists in order to give patients a more holistic approach to treatment.

His reasons for opening the center are multi-faceted. Not only does he want to right perceptions related to the disease, he also seeks to evaluate the disease at all stages, along with the impact on a persons life and the community.

Memphis is an epicenter for diabetes, with Tennessee ranking fifth in the nation in its adult obesity rate. More than 29 million people in the U.S. have diabetes, with an estimated 8 million of those being undiagnosed.

Patients whose bodies do not produce enough insulin are called Type 1 diabetics. Type 2 diabetics produce enough insulin, but they have insulin resistance so there are times when medication, lifestyle changes and sometimes insulin are needed.

We offer services catered specifically to both classifications of diabetes, Latif said. The cornerstone of treatment is lifestyle changes, and we are very specific about the kinds of exercise and dietary changes people need to undertake to treat the disease.

Educating newly diagnosed patients and their families about diabetes and its treatment is a big emphasis for the clinic.

We really take pride in our education here, said Lesley Draffin, a registered nurse at the clinic. We have a comprehensive diabetes class every Wednesday and at the end of every month.

The center also offers services involving medication, and one of the ways to administer insulin is an insulin pump.

We have a longstanding experience with using insulin pumps, so for the last three years we have created a separate space or a sub-center for patients who are on insulin pumps, he said. All of the personnel that they come in contact with have an added level of expertise as far pump functions, etc.

In fact, all of the staff at the AM Diabetes and Endocrinology Center are required to try out wearing one of the pumps.

The patients really like that because it lets them know that we know what theyre feeling, said Draffin.

This spring, a more advanced insulin pump that can automatically administer insulin based on a blood-glucose sensor placed under the skin will be available for use in the marketplace. Latif presented research gathered at his clinic on the effectiveness of the new pumps at the American Association of Clinical Endocrinology national meeting last year, and the FDA approved the closed loop system last September.

We showed that just by moving patients under the specialized insulin pump center model, we were able to reduce their A1C levels, which is a measure of how much the blood glucose is controlled, significantly, Latif said. Once we publish more research and get the word out, I hope well see more insulin pump centers across the country because I think that is the way of the future.

His center works at the community level to raise awareness and funds for research.

His center also is intimately involved with the Juvenile Diabetes Research Foundation (JDRF) and its efforts of fundraising, awareness and treatment of the disease, Latif said.

Five years ago, the center started the Sugar Run 5K, which has to date raised more than $120,000 all going to JDRF for juvenile diabetes research. The run is held every year in November at Jonathan Park in Collierville.

The center partners with radio host Betty Lamar every Saturday at noon for a diabetes and endocrinology hour, The Betty Lamar Show, on KWAM-990. Her show helps educate the public about diabetes care in general as well as services available at AM Diabetes.

At the center, they actually sit down so they can do a one-on-one with people, so no matter what your educational level they really give a wonderful class and all kinds of great reading material, said Lamar, who has a close family member who receives treatment for a thyroid problem at AM Diabetes.

Another goal of the center is to get the appropriate care to underprivileged children.

So many underprivileged children with juvenile diabetes really dont get the care they need, said Lamar, whose father had diabetes. You just cant get an insulin pump if you are poor. He wants to reach out and get those children on an insulin pump, or at least under his care.

Next, Latif hopes over the next couple of years to develop an online monitoring system for patients who wear glucose sensors as well as develop a registry for patients with Type 1 diabetes in Shelby County and the surrounding areas.

More:
Son's Diagnosis Fuels Multifaceted Approach to Treating Diabetes - Memphis Daily News

Posted in Diabetes | Comments Off on Son’s Diagnosis Fuels Multifaceted Approach to Treating Diabetes – Memphis Daily News

On Second Attempt, SpaceX Launches Rocket At NASA’s Historic Pad – Alabama Public Radio

Posted: February 20, 2017 at 4:42 pm

To paraphrase an age-old saying: If at first you don't succeed, well, dust off the historic launch pad and try another liftoff.

Not as catchy as the original, perhaps, but certainly fitting for SpaceX, which succeeded Sunday on its second launch attempt at NASA's Launch Complex 39A, at Kennedy Space Center in Florida. The first attempt, scrubbed Saturday with just 13 seconds before liftoff, was foiled by concerns over an anomaly discovered in the rocket's steering system.

The issue was "99% likely to be fine," Elon Musk, founder of the private space company, tweeted Saturday, "but that 1% chance isn't worth rolling the dice. Better to wait a day."

On Sunday, however, the launch went smoothly. Not only did SpaceX's Falcon 9 rocket lift off without a hitch, its first stage also returned to land right back on a platform on Earth. Shortly afterward, the Dragon spacecraft it was carrying detached as planned from the rocket.

While there's nothing particularly rare about the 5,500 pounds of cargo strapped into that spacecraft which is destined for the International Space Station the pad it took off from has quite a backstory: Launch Complex 39A was the site that sent the first humans to the moon in the 1969 Apollo 11 mission.

It was the pad for a number of NASA's most important missions from its early days sending people to space, to the three decades of the space shuttle program.

Now the pad, which hadn't been used since that program ended in 2011, is getting dusted off for a new era "as a spaceport open for use by public and commercial missions to space," NPR's Rae Ellen Bichell reported for our Newscast unit.

As we noted Saturday, NASA says SpaceX's resupply mission packs supplies and materials for more than a few experiments:

"Science investigations launching on Dragon include commercial and academic research investigations that will enable researchers to advance their knowledge of the medical, psychological and biomedical challenges astronauts face during long-duration spaceflight.

"One experiment will use the microgravity environment to grow stem cells that are of sufficient quality and quantity to use in the treatment of patients who have suffered a stroke. A Merck Research Labs investigation will test growth in microgravity of antibodies important for fighting a wide range of human diseases, including cancer."

Reuters reports that NASA is also carefully monitoring the launch by SpaceX, which it "hired to fly cargo to the station after the shuttle program ended." The news service says NASA wants "to learn more about SpaceX's operations before it clears the company to fly NASA astronauts on SpaceX rockets."

See the original post here:
On Second Attempt, SpaceX Launches Rocket At NASA's Historic Pad - Alabama Public Radio

Posted in Alabama Stem Cells | Comments Off on On Second Attempt, SpaceX Launches Rocket At NASA’s Historic Pad – Alabama Public Radio

This Biotech ETF Looks Primed To Rally Again – ETF Daily News (blog)

Posted: February 20, 2017 at 4:42 pm

February 20, 2017 6:42am NASDAQ:IBB

The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a loss of more than 20%, has started posting gains again and is looking like the rally may be poised to continue.

The biggest play in the sector, the iShares Nasdaq Biotechnology ETF (IBB), is up more than 10% on the year (its smaller equal weight counterpart, the SPDR S&P Biotech ETF (XBI), is up over 17%).

The sector has alternatively gotten good and bad news from the White House. For many months, there has been talk of lowering drug prices through open competition or price caps putting pressure on the big drug manufacturers. On the other hand, President Trump spoke recently of his desire to reform the entire drug approval process in order to speed the approval of life-saving medications and cutting the red tape at the FDA. That notion was welcomed by the equity markets even though it received a tepid response from big pharma companies.

One thing working in favor of biotech right now is M&A and the big prize could be Bristol-Myers Squibb (BMY). A StreetInsider article from this week called the company in play and listed Roche (RHHBY), Novartis (NVS), Gilead (GILD) and Pfizer (PFE) all as potential buyers. Acadia Pharmaceuticals (ACAD) could also be up for grabs with Biogen (BIBB) rumored to be a possible bidder. In its quarterly analyst meeting, Amgens (AMGN) CEO Bob Bradway discussed how his company was going to be on the lookout for acquisitions both big and small.

Even Gilead, the big biotech that just caught Wall Street off guard when it significantly lowered 2017 revenue guidance due to weak sales in its hepatitis C drugs, even provided some reason for optimism. The stock dropped roughly 10% on its weak forecast, from a pre-earnings level of around $73 down to a post-announcement low in the $65 area. Since then, however, it has, somewhat surprisingly, begun rallying anew. The stock closed Friday at $70, gaining back nearly of what was lost. Does this signal something of a capitulation point and indicate that buyers are ready to return?

From a technical standpoint, the fund just broke out to the upside from a wedge pattern that has been forming over the past several months.

I wrote earlier this month that I felt the Biotech ETF could close out February above $300 if it could break through the resistance level around $285. It has and now it feels like that $300 level is well within reach.

Despite its rally so far this year, the fund is still about 13% off of its 2016 highs and 26% off of its all-time highs. Valuations in the sector look very reasonable right now as well. Thomson Reuters estimates put the forward P/E of the sector at less than 13, a level it hasnt seen in several years.

Gileads results notwithstanding, the Q4 earnings season has been pretty good for biotech. Big players such as Amgen, Celgene (CELG), Illumina (ILMN) and Vertex Pharmaceuticals (VRTX) all top 10 holdings in the fund popped strongly after announcing earnings. If the sector can continue posting generally good revenue and earnings results and get a little help from the White House along the way, this could be a nice spot to add a few shares.

The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) closed at $294.35 on Friday, up $1.37 (+0.47%). Year-to-date, IBB has gained 10.92%, versus a 5.17% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

About the Author: David Dierking

David Dierking is a freelance writer focusing primarily on ETFs, mutual funds, dividend income strategies and retirement planning. He has spent more than 20 years in the financial services industry and his background includes experience in investment management, portfolio analytics and asset/liability management at both BMO Financial Group and Strong Capital Management.

He has written for Seeking Alpha, Motley Fool, ETF Trends and Investopedia and was also included in the panel for ETFReference.coms 101 ETF Investing Tips from the Experts. He has a B.A. in Finance from Michigan State University and lives in Wisconsin with his wife and two daughters.

You can connect with David on Twitter and LinkedIn. Also be sure to visit his new website, ETFFocus.com.

Tags: biotech david dierking NASDAQ:IBB

Categories: NASDAQ:IBB

See more here:
This Biotech ETF Looks Primed To Rally Again - ETF Daily News (blog)

Posted in Biotechnology | Comments Off on This Biotech ETF Looks Primed To Rally Again – ETF Daily News (blog)

Worldwide Animal Health Biotechnology Market by Analysis of Major Industry Segments 2024 – Digital Journal

Posted: February 20, 2017 at 4:42 pm

Transparency Market Research Report Added "Animal Health Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024"

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 02/20/2017 -- Animal Health Biotechnology Market: Overview

Biotechnology utilized in animal healthcare dates back to 19th century when the first vaccines were prepared for its use in animals. Considerable progress in the animal health biotechnology took place recently when biotechnology applications were utilized in both detecting and treating various infectious and parasitic diseases of animals. This has led to the development of a range of applications and procedures, which will benefit both domestic and wild animals. This will also improve the health of various companion animals, help in improving sporting animals' performance and the productivity of farm animals. However, the globalised trade in live animals, animal products, and their feeds is leading to a continuously increasing threat of infectious diseases worldwide. Thus, to prevent the spread of infectious diseases, the World Organization for Animal Health (OIE) emphasizes the importance of very rapid, accurate, highly specific and sensitive detection and identification of infectious agents; and prompt and effective control of those diseases.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Download PDF brochure for this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11465

Animal Health Biotechnology Market: Current Outlook

Presently, various reagents and diagnostic techniques have been developed, which are more specific, sensitive, rapid, reproducible and robust that have been updated through recent discoveries in biochemistry, immunology and molecular biology (monoclonal antibodies, nucleic probes, DNA amplification and others). The development of new vaccines, such as subunit vaccines, synthetic vaccines, recombinant vaccines and anti-idiotype vaccines, which combine efficacy, innocuity, duration of protection, ease of use, stability and multivalence. The availability of new anti-parasitic and anti-infective agents and immunomodulatory therapeutic agents specifies that biotechnology is continuing to find new applications in the field of animal health. These new vaccines, diagnostic techniques, and therapeutic substances will add to the knowledge, which, in future, will extend to the development of transgenic animals with improved genetic potential and will be more disease resistant and more productive at the same time. Thus, the most important objective of animal health biotechnology is to serve human healthcare as well as its environment at the same time.

Animal Health Biotechnology Market: Drivers

Major factors that will drive the demand from this market mainly includes advancements in cloning and development of transgenic animals, favorable government approval scenarios, and increasing research and development from major firms across the globe. Development of various transgenic animals and cloning will add to the animal's ability to fight diseases and at the same time it will benefit the human society and environment. This will increase the demand for these animals; hence will contribute towards the growth of animal health biotechnology market in the future. Favorable government policies as well as supportive approval agencies will further help in the growth of this market in future. Major firms across geographies are conducting extensive R&D, which will add to the development of advanced vaccines, therapeutics as well as transgenic animals, will add to the growth of this market in future.

Animal Health Biotechnology Market: Regional Dynamics

Geographically, North America and Europe is expected to dominate the Animal Health Biotechnology market. Major factors that will be responsible for their growth in this market can be high awareness levels of the population about cloning, transgenic products etc. and high investment in research and development activities from both public and private firms in these regions. Asia-Pacific region is also expected to show a rapid growth in this market due to availability of huge livestock population as well as dependency of various regions on animals for their daily activities. Some of the major players operating in the animal health biotechnology market are Bayer AG, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Santa Cruz Biotechnology, Inc.

Browse Full Research Report on Animal Health Biotechnology Market: http://www.transparencymarketresearch.com/animal-health-biotechnology-market.html

About Transparency Market Research Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector - such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact: Transparency Market Research 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com Browse market research blog: https://tmrresearch.blogspot.com/

For more information on this press release visit: http://www.sbwire.com/press-releases/worldwide-animal-health-biotechnology-market-by-analysis-of-major-industry-segments-2024-772649.htm

Excerpt from:
Worldwide Animal Health Biotechnology Market by Analysis of Major Industry Segments 2024 - Digital Journal

Posted in Biotechnology | Comments Off on Worldwide Animal Health Biotechnology Market by Analysis of Major Industry Segments 2024 – Digital Journal

Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

Posted: February 20, 2017 at 4:42 pm

New research provides further evidence of autologous hematopoietic stem cell transplantation as an effective treatment for multiple sclerosis, after finding the procedure halted disease progression for 5 years in almost half of patients.

Lead study author Dr. Paolo Muraro, of the Department of Medicine at Imperial College London in the United Kingdom, and colleagues recently reported their findings in JAMA Neurology.

The results come just a fortnight after another study revealed the success of a similar treatment in a small group of patients with relapsing-remitting multiple sclerosis (RRMS).

However, Dr. Muraro and team warn that further trials are needed to determine the efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT), after a small number of patients died within 100 days of treatment.

In AHSCT, a patient's own stem cells are harvested. The patient is then subject to high-dose chemotherapy to eliminate any diseased cells.

Next, the harvested stem cells are returned to the patient's bloodstream, with the aim of restarting normal blood cell production. In simple terms, AHSCT "resets" the immune system.

"We previously knew this treatment reboots or resets the immune system - and that it carried risks - but we didn't know how long the benefits lasted," notes Dr. Muraro.

For their study, the researchers assessed data from 25 treatment centers across 13 countries, identifying 281 patients with multiple sclerosis (MS) who underwent AHSCT between 1995-2006. Of these patients, 78 percent had a progressive form of MS.

Using the Expanded Disability Status Scale (EDSS), the team evaluated patients' progression-free survival at 5 years after treatment and any improvements in MS symptoms.

An EDSS score of zero represents no disability, seven represents the use of a wheelchair, while 10 represents death from MS. At the beginning of the study, patients had an average EDSS score of 6.5.

Overall, the researchers found that 46 percent of patients experienced no disease progression in the 5 years after treatment.

Patients with RRMS - characterized by inflammatory attacks, or "flare-ups," followed by periods of remission - had the best outcomes, with 73 percent experiencing no worsening of symptoms in the 5 years after AHSCT.

Additionally, patients experienced small improvements in MS symptoms after AHSCT. Patients with progressive MS saw their EDSS score rise by 0.14 a year after treatment, while patients with RRMS experienced a 0.76 increase in their EDSS score.

Patients with a younger age, few immunotherapies prior to AHSCT, and a lower EDSS score at study baseline also showed better outcomes with AHSCT.

While these findings show promise for the use of AHSCT for patients with MS, the team notes that there were eight deaths in the 100 days after AHSCT, which were thought to have been treatment related.

AHSCT involves aggressive chemotherapy, which can severely weaken the immune system and increase susceptibility to infection.

"In this study, which is the largest long-term follow-up study of this procedure, we've shown we can 'freeze' a patient's disease - and stop it from becoming worse, for up to 5 years.

However, we must take into account that the treatment carries a small risk of death, and this is a disease that is not immediately life-threatening."

Dr. Paolo Muraro

Dr. Muraro notes that, importantly, this study did not include a group of MS patients who did not receive treatment, further highlighting the need for more studies assessing the safety and efficacy of AHSCT.

"We urgently need more effective treatments for this devastating condition, and so a large randomized controlled trial of this treatment should be the next step," he adds.

Read about a study that links vitamin D level at birth to the risk of MS.

See more here:
Multiple sclerosis: Stem cell transplantation may halt disease progression - Medical News Today

Posted in Cell Medicine | Comments Off on Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

Augmented adoptive cell transfer eradicates solid tumors [PreClinical] – 2 Minute Medicine

Posted: February 20, 2017 at 4:42 pm

1. Combining tumor-specific T cells and pathogen-based immune stimulation, reenergized adoptive cell transfer (ReACT) targeted and eradicated tumor cells in mice.

2. ReACT led to increased migration of activated T cells to the tumors, a metric that correlated with decreased tumor size.

Evidence Rating Level: 2 (Good)

Study Rundown: Because cancer cells can evade being targeted by the bodys immune system, therapies have been developed to alter the tumors immune microenvironment. One therapy, adoptive cell transfer (ACT), involves engineering T cells to target cells that express tumor-associated antigens (TAAs). Although this therapy has potential, the tumor microenvironment causes inhibition of T cell function, preventing the therapys long-term efficacy. Another approach has been to use pathogens that express TAAs to stimulate the immune system. However, since some tumor cells have altered TAAs, they evade being targeted. In this study, these two approaches were combined into a therapy named ReACT: T cells were engineered to target a TAA as well as a bacterial antigen, and the cells were administered along with a bacterial adjuvant.

When treated with ReACT, a majority of mice with implanted melanoma cells experienced tumor eradication. An increased frequency of T cells in the tumor environment correlated with decreased tumor size. In addition, biomarker levels indicated effective T cell migration and activation. A polyclonal form of ReACT was also tested in a mouse model of melanoma; following tumor eradication in these mice, more tumor cells were introduced but failed to survive, demonstrating an immunological memory response induced by this therapy.

This study demonstrated a new approach for a safer and more efficacious cancer immunotherapy. Future studies will need to more closely mimic a clinical model and provide specific data describing the mechanism of T cell function in this therapy.

Click to read the study in PNAS

Relevant Reading: Cancer Immunotherapy: Strategies for Personalization and Combinatorial Approaches

In-Depth [animal study]: The researchers obtained CD8 T cells that expressed a T cell receptor (TCR) that recognizes a TAA specific to murine melanoma cells. These T cells were then engineered to express a TCR that recognizes the antigen ovalbumin (OVA). In mice with melanoma tumors, this treatment was only effective when the T cells were administered in conjunction with OVA conjugated to Listeria (LM-OVA), a model organism used for pathogen-based cancer vaccines. Seven out of 10 mice experienced complete tumor cell eradication (p<0.001). Neither the engineered T cells alone nor the LM-OVA alone was sufficient to produce significant tumor regression.

Next, the properties and functions of the ReACT T cells were analyzed. The CD8 T cells were present at a higher frequency in the ReACT-treated mice and this value negatively correlated to tumor size, with an r-value of -0.699. These T cells had an activated phenotype, with an increased expression of CD44 and other transcription factors as well as a decreased expression of inhibitory receptors such as CTLA-4. These T cells also had a high expression of CXCR3, a chemokine receptor involved in migration to tumor cells.

Finally, polyclonal ReACT was tested in mice with melanoma tumors. Tumor-specific CD8 T cells were generated by stimulating them with dendritic cells presenting a pool of TAAs; the cells were additionally engineered to express the OVA TCR, and administered to mice along with LM-OVA. Eleven out of 16 mice experienced complete tumor eradication. These mice were then reintroduced to the same melanoma cell line and were resistant to tumor relapse, demonstrating the establishment of an immunological memory response.

Image: PD

2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

2 Minute Medicines The Classics in Medicine: Summaries of the Landmark Trials is available now in paperback and e-book editions.

This text summarizes the key trials in:General Medicine and Chronic Disease, Cardiology, Critical and Emergent Care, Endocrinology, Gastroenterology, Hematology and Oncology, Imaging, Infectious Disease, Nephrology, Neurology, Pediatrics, Psychiatry, Pulmonology, and Surgery.

See original here:
Augmented adoptive cell transfer eradicates solid tumors [PreClinical] - 2 Minute Medicine

Posted in Cell Medicine | Comments Off on Augmented adoptive cell transfer eradicates solid tumors [PreClinical] – 2 Minute Medicine

Here’s Why Organoids Are a Game Changer in Medical Research – Newsweek

Posted: February 20, 2017 at 4:42 pm

This article was originally published on The Conversation. Read the original article.

Most of the research behind new medical advances is carried out using either animal tissues or cancer cells. Both tools have their problems: results from animals and humans do not always match up and cancer cells grown for years in laboratories often do not mimic the tissues they originally came from very well. Bridging the gap between whole animals and simple cells can be a challenge during the development of new treatments, but this is beginning to change since scientists have learned how to grow organoids.

Organoids are clusters of cells that organize themselves into mini versions of our organs. They are grown from stem cells, and their use has only become possible with the discovery of the precise conditions needed to keep stem cells alive outside the body. Organoids were first made from intestines but have since been made using many other tissues, including liver, breast and even brain cells. This will allow scientists to better study the development and diseases of these organs.

Try Newsweek for only $1.25 per week

An engineer from CNRS (French Reseach Institut Center) introduces embryonic stem cells in a mouse embryo to set a genetically modified line, Marseille, France, February 9, 2012. Organoidslab-grown miniature versions of organsare proving to be a game changer in the field of medical research. Anne-Christine Poujoulat/AFP/Getty Images

They are grown in a gel that allows them to develop three-dimensionally, so they mimic the architecture of our organs much more realistically than a simple layer of cells. Stem cells from the intestine multiply to form a ball, in which the hollow centeris like the space inside the intestine. The surface of these balls then buds outwardat various points to form pocket-like extensions. This is similar to the intensely folded surface of the gut wall.

Organoids have several advantages over existing approaches. Stem cells are taken from animals or patients and continually multiply so the organoids can be maintained for months. They provide an unlimited supply of material for study, meaning fewer animal studies are required. Making organoids from patients also raises intriguing possibilities for personalized medicine.

In traditional cell cultures every cell is identical but stem cells can form many different cell types, so organoids contain a much more realistic mixture of cells. For example, M cells are specialized cells in the gut wall that act as surveillance posts, capturing bacteria from the gut and showing them to the immune system so it can monitor for danger. Some harmful bacteria exploit this to invade the gut wall. It was previously tricky to grow M cells in the lab for study, but they can be grown in organoids. When added to organoids, Salmonella, a bacterium that causes food poisoning, infected M cells more often than other cell types, suggesting this may be a route of infection in humans.

Some common disease-causing bacteria are surprisingly difficult to grow in the lab, making them hard to study. Clostridium difficile causes numerous cases of diarrhoea every year, a serious condition in frail patients. It has been difficult to grow C. difficile because it requires conditions without oxygen, but researchers in the U.S. have shown that the bug can survive inside intestinal organoids. Bacteria were injected into the centerof intestinal organoids and produced a toxin that made the organoid wall leakier, damaging its ability to act as a barrier.

Organoids made from patient biopsies are allowing us to investigate differences between individuals. Patients with cystic fibrosis show varied responses to treatments. One group of researchers grew organoids from patient biopsies and tested their response to different combinations of drugs. In the future this may be used to quickly find the best treatment for each individual.

Tumors also vary hugely between individuals. Dutch researchers grew organoids from patients with colorectal tumors and identified genetic changes that had occurred in the tumour cells compared to the patients healthy tissue. They were then able to see how these altered the way the cells behaved. They tested anti-cancer drugs on the organoids and could tell which drugs did and did not kill the tumor cells.

Imagine if organoids were routinely made from tumor biopsies and used to identify the best chemotherapy combination for each patient. This is certainly plausible, but the process will first need to be made quicker and cheaper.

All this makes organoids an exciting new tool for researchers. Most work currently focuses on the stomach and intestine, but the technique is quickly expanding to other tissues, such as liver, breast and brain. Organoids will transform the way we conduct medical research, from basic understanding to drug development and personalized therapies. Expect to hear much more about them in the future.

Louise ThompsonisPhD candidate in Molecular and Cellular Physiology at theUniversity of Liverpool.

Read more from the original source:
Here's Why Organoids Are a Game Changer in Medical Research - Newsweek

Posted in Cell Medicine | Comments Off on Here’s Why Organoids Are a Game Changer in Medical Research – Newsweek

Mayo doc’s stem cell experiment blasts into space – Post-Bulletin

Posted: February 20, 2017 at 4:42 pm

JACKSONVILLE, Fla. As a boy growing up in Kano, Nigeria, Dr. Abba Zubair dreamed of going to space.

On Sunday, his work hitched a ride with a private rocket blasting off from NASA's Kennedy Space Center in Cape Canaveral, Fla., on a trip to the International Space Station.

Dr. Zubair, an associate professor of laboratory medicine and pathology at the Mayo Clinic's Florida campus, prepared a science package involving stem cells as part of a resupply mission to the ISS aboard a SpaceX Falcon 9 rocket.

"It was my first rocket launch view," said Dr. Zubair, who was on hand to watch and listen to the deafening sound as his experiment rode into space. "It was incredible."

The stem cells -- specialized cells derived from bone marrow come from Dr. Zubair's lab. Dr. Zubair, according to a report from the Mayo Clinic, specializes in cellular treatments for disease and regenerative medicine. He hopes to find out how the stem cells hold up in space and if they can be more quickly produced in microgravity.

More specifically, Zubair said, he is hoping the research can help in treatment of patients who have suffered a stroke-related brain injury.

"Stem cells are known to reduce inflammation," he said in a press release. "We've shown that an infusion of stem cells at the site of stroke improves the inflammation and also secretes factors for the regeneration of neurons and blood vessels."

The problem with such a treatment and studying the treatment is generating enough stem cells for the job. Based on current regenerative medicine studies, patients need at least 100 million stem cells for an effective dose. However, reproducing stem cells can be time consuming since the cells naturally limit their numbers.

"Scalability is a big issue," Dr. Zubair said. "I've been interested in a faster way to make them divide."

And on earth, everything is impacted by gravity, from how high we grow to our bone size and other physiological traits. "So, how can we use the effect of gravity to impact how the cells divide?" he asked.

Experiments that simulate stem cell growth in microgravity, thus far, have shown cells do grow more quickly than experimental controls, he said. So he began working toward getting an experiment into space. The experiment needed to be designed so the crew onboard the space station could run the experiment with some simple training, and Dr. Zubair will be able to watch the experiment in real time via a video connection. "We'll get some data as early as next week," he said.

If all goes well, growing stem cells in space something Dr. Zubair admits sounds like a dream of the distant future might become a reality more quickly than many people think.

"There are some companies interested in floating labs," he said. "I think the future is bright. There are a lot of possibilities in the area of regenerative medicine."

Read more here:
Mayo doc's stem cell experiment blasts into space - Post-Bulletin

Posted in Cell Medicine | Comments Off on Mayo doc’s stem cell experiment blasts into space – Post-Bulletin